Yujin Kim

Yujin Kim

Auto-generated profile, based on publicly available information

Yujin Kim

Paean Biotechnology Inc., Seoul, South Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in BMB Reports
Verified
Journal Article
Open access
PDF file
SYShin-Hye Yu
Shin-Hye Yu
SKSoomin Kim
Soomin Kim
YKYujin Kim
Yujin Kim
SLSeo-Eun Lee
Seo-Eun Lee
JPJong Hyeok Park
Jong Hyeok Park
CKChun-Hyung Kim
Chun-Hyung Kim
Shin-Hye Yu, Soomin Kim, Yujin Kim, Seo-Eun Lee, Jong Hyeok Park, Gayoung Cho, Jong-Cheon Ha, Hahnsun Jung, Sang-Min Lim, Kyuboem Han, Hong Kyu Lee, Young Cheol Kang & Chun-Hyung Kim. BMB Reports 2022;55:136-41. https://doi.org/10.5483/BMBRep.2022.55.3.083

31 August 2024 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
BKBong Jik Kim
Bong Jik Kim
YKYujin Kim
Yujin Kim
JKJu Ang Kim
Ju Ang Kim
JHJin Hee Han
Jin Hee Han
MKMin Young Kim
Min Young Kim
Byung Yoon ChoiByung Yoon Choi
Byung Yoon Choi
Objectives. FDXR encodes mitochondrial ferredoxin reductase, which is associated with auditory neuropathy spectrum disorder (ANSD) and optic atrophy. To date, only two studies have described FDXR-related hearing loss. The auditory rehabilitation outcomes of this disease entity have not been investigated, and the pathophysiological mechanisms remain incompletely understood. Here we report a hearing-impaired individual with co-segregation of the FDXR variant and post-synaptic type ANSD, who underwent cochlear implantation (CI) with favorable outcomes. We suggest a possible pathophysiological mechanism of adult-onset ANSD involving mitochondrial dysfunction.Methods. A 35-year-old woman was ascertained to have ANSD. Exome sequencing identified the genetic cause of hearing loss, and a functional study measuring mitochondrial activity was performed to provide molecular evidence of pathophysiology. Expression of FDXR in the mouse cochlea was evaluated by immunohistochemistry. Intraoperatively, electrically evoked compound action potential (ECAP) responses were measured, and the mapping parameters were adjusted accordingly. Audiological outcomes were monitored for over 1 year.Results. In lymphoblastoid cell lines (LCLs) carrying a novel FDXR variant, decreased ATP levels, reduced mitochondrial membrane potential, and increased reactive oxygen species levels were observed compared to control LCLs. These dysfunctions were restored by administering mitochondria isolated from umbilical cord mesenchymal stem cells, confirming the pathogenic potential of this variant via mitochondrial dysfunction. Partial ECAP responses during CI and FDXR expression in the mouse cochlea indicate that FDXR-related ANSD is post-synaptic. As a result of increasing the pulse width during mapping, the patient’s CI outcomes showed significant improvement over 1-year post-CI.Conclusion. A novel FDXR variant associated with mitochondrial dysfunction and post-synaptic ANSD was first identified in a Korean individual. Additionally, 1-year post-CI outcomes were reported for the first time in the literature. Excellent audiologic results were obtained, and our results reiterate the correlation between genotype and CI outcomes in ANSD.